Orphan Therapies: Making Best Use of Postmarket Data

Orphan Therapies: Making Best Use of Postmarket Data

Postmarket surveillance of the comparative safety and efficacy of orphan therapeutics is challenging, particularly when multiple therapeutics are licensed for the same orphan indication. To make best use of product-specific registry data collected to fulfill regulatory requirements, we propose the c...

Full description

Bibliographic Details
Main Authors: Li, Lingling, Brown, Jeffrey S., Pan, Gerald J. Dal, Maro, Judith
Other Authors: Massachusetts Institute of Technology. Center for Biomedical Innovation
Format: Article
Language:English
Published: Springer US 2016
Online Access:http://hdl.handle.net/1721.1/103520
https://orcid.org/0000-0001-9900-2142

Internet

http://hdl.handle.net/1721.1/103520
https://orcid.org/0000-0001-9900-2142

Similar Items